Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion studyUdai Banerji, Philippe Aftimos, Carla M.L. van Herpen et al.|The Lancet Oncology|2019Cited by 564
Tipifarnib in Head and Neck Squamous Cell Carcinoma With<i>HRAS</i>MutationsAlan L. Ho, Antonio Gualberto, Robert I. Haddad et al.|Journal of Clinical Oncology|2021Cited by 196
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid TumorsThierry André, Susana Banerjee, Dominique Berton et al.|JAMA Network Open|2023Cited by 120
A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with <i>RET</i>-altered cancers.Alexander Drilon, Lori J. Wirth, Vivek Subbiah et al.|Journal of Clinical Oncology|2018Cited by 104
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid TumorsMichael L. Maitland, Emiliano Calvo, Jasgit C. Sachdev et al.|Clinical Cancer Research|2021Cited by 81